CO2019004814A2 - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica - Google Patents

Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica

Info

Publication number
CO2019004814A2
CO2019004814A2 CONC2019/0004814A CO2019004814A CO2019004814A2 CO 2019004814 A2 CO2019004814 A2 CO 2019004814A2 CO 2019004814 A CO2019004814 A CO 2019004814A CO 2019004814 A2 CO2019004814 A2 CO 2019004814A2
Authority
CO
Colombia
Prior art keywords
atherosclerosis
pcsk9
ldl
therapies
cardiovascular disease
Prior art date
Application number
CONC2019/0004814A
Other languages
English (en)
Spanish (es)
Inventor
Ransi Mudalinayake Somaratne
Robert Andrew Donald Scott
Scott Wasserman
Narimon Honarpour
Stephen Nicholls
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019004814(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO2019004814A2 publication Critical patent/CO2019004814A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CONC2019/0004814A 2016-11-14 2019-05-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica CO2019004814A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10
PCT/US2017/061346 WO2018089912A2 (en) 2016-11-14 2017-11-13 Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease

Publications (1)

Publication Number Publication Date
CO2019004814A2 true CO2019004814A2 (es) 2019-07-31

Family

ID=60484496

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0004814A CO2019004814A2 (es) 2016-11-14 2019-05-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica

Country Status (17)

Country Link
US (1) US20200368350A1 (OSRAM)
EP (1) EP3538149A2 (OSRAM)
JP (3) JP2019533715A (OSRAM)
KR (2) KR20190085963A (OSRAM)
CN (1) CN110234350A (OSRAM)
AU (2) AU2017356219A1 (OSRAM)
BR (1) BR112019009726A2 (OSRAM)
CA (1) CA3043700A1 (OSRAM)
CL (2) CL2019001304A1 (OSRAM)
CO (1) CO2019004814A2 (OSRAM)
IL (1) IL266579A (OSRAM)
JO (1) JOP20190112A1 (OSRAM)
MA (1) MA46758A (OSRAM)
MX (3) MX2019005627A (OSRAM)
TN (1) TN2019000156A1 (OSRAM)
WO (1) WO2018089912A2 (OSRAM)
ZA (1) ZA201902975B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010927A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
JP2021533190A (ja) * 2018-07-31 2021-12-02 タン ウェンTAN, Wen ＬＤＬコレステロールの細胞内クリアランスを増強しかつスタチンとの併用療法で効力を高めかつ副作用を減らすための、カルバメートβフェニルエタノールアミン類似体の新規使用法
US20220245219A1 (en) * 2019-07-19 2022-08-04 Ebay Inc. Sample Delta Monitoring
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103614375A (zh) 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010078536A1 (en) * 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
EA201270019A1 (ru) 2009-06-15 2012-06-29 Элнилэм Фармасьютикалз, Инк. Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
SG191219A1 (en) 2010-12-22 2013-07-31 Genentech Inc Anti-pcsk9 antibodies and methods of use
KR20140006022A (ko) 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
MX388989B (es) * 2015-01-09 2025-03-11 Global Genomics Group Llc Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска

Also Published As

Publication number Publication date
JP2025102770A (ja) 2025-07-08
AU2024278180A1 (en) 2025-01-09
WO2018089912A2 (en) 2018-05-17
MX2024000805A (es) 2024-02-06
AU2017356219A1 (en) 2019-05-30
WO2018089912A3 (en) 2018-06-21
CL2019001304A1 (es) 2019-09-23
CN110234350A (zh) 2019-09-13
CA3043700A1 (en) 2018-05-17
IL266579A (en) 2019-07-31
CL2020002993A1 (es) 2021-05-14
MA46758A (fr) 2019-09-18
JOP20190112A1 (ar) 2019-05-14
TN2019000156A1 (en) 2020-10-05
ZA201902975B (en) 2020-01-29
KR20190085963A (ko) 2019-07-19
MX2019005627A (es) 2019-10-14
US20200368350A1 (en) 2020-11-26
JP2019533715A (ja) 2019-11-21
JP2023071715A (ja) 2023-05-23
MX2025002106A (es) 2025-04-02
KR20240096648A (ko) 2024-06-26
EP3538149A2 (en) 2019-09-18
BR112019009726A2 (pt) 2019-08-13

Similar Documents

Publication Publication Date Title
CO2019004814A2 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2018005165A (es) Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2017016774A (es) Agente terapeutico para la fibrosis.
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
AR087790A1 (es) Uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
MX2019010931A (es) Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia.